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Staphylococcus epidermidis is a major cause of infections associated with indwelling medical devices. Biofilm
production is an important virulence attribute in the pathogenesis of device-related infections. Therefore,
elimination of these biofilms is an ideal treatment. Salicylate (5 mM) combined with 1 g of vancomycin per
ml inhibited biofilm formation by S. epidermidis (RP62A) by >99.9%. When biofilm-coated polystyrene beads
were exposed to 5 mM sodium salicylate and 4 g of vancomycin per ml (one-half the minimum biofilm
eradication concentration), there was a >99.9% reduction in viable count.
Catheter-related infections are among the most common
nosocomial infections, accounting for significant morbidity and
mortality (27, 32). In 1992, the annual cost incurred by these
infections in the United States was estimated to exceed $4.5
billion (24). The most common etiologic agent of catheter-
related infection is Staphylococcus epidermidis (15, 20, 35).
Vancomycin is often used to treat these infections because of
the frequent occurrence of methicillin-resistant coagulase-neg-
ative staphylococci, including S. epidermidis. Vancomycin effi-
cacy is reduced when S. epidermidis exists within a biofilm on
the surfaces of indwelling medical devices (18, 31). Biofilm-
producing S. epidermidis is usually involved in catheter-related
infections (1, 33, 36). Resistance of biofilm bacteria to antibi-
otics may be due to a variety of factors, including changes in
cell wall composition and surface structures (1, 2, 33). In view
of the difficulty of the treatment of infections due to biofilm-
producing bacteria, various measures for the prevention and
treatment of catheter-related infections are being investigated.
One intervention uses implants coated or impregnated with
antimicrobial agents (8, 16, 22, 23, 26, 27).
Sodium salicylate has been demonstrated to have remark-
able antibacterial activity, including the ability to enhance the
activities of certain antibiotics. This drug inhibits adherence
(55%), growth, and biofilm production of S. epidermidis (13,
28). It also enhances the in vitro and in vivo activities of
amikacin against Klebsiella pneumoniae (10, 11) and increases
the synergistic activity of imipenem and amikacin when they
are used to treat K. pneumoniae infections in animals. The
combined effect of vancomycin and sodium salicylate on S.
epidermidis biofilms has not been reported. This study was
designed to investigate the effect of sodium salicylate on the
ability of vancomycin to inhibit biofilm production by S. epi-
dermidis and to kill the bacteria.
S. epidermidis RP62A (ATCC 35984) was obtained from the
American Type Culture Collection (ATCC), and S. epidermidis
(M7) and Staphylococcus aureus (ATCC 29213) were kind con-
tributions of M. Hussain (Institute of Medical Microbiology,
Muenster, Germany) and S. L. Josephson (Rhode Island Hos-
pital, Providence, R.I.), respectively. Inhibition of biofilm for-
mation was confirmed by an adherence-biofilm assay described
previously (3, 4, 5 6, 21). Biofilm-negative mutant S. epidermi-
dis M7 (34) served as a control. Briefly, aliquots (300 l) of
overnight cultures of S. epidermidis RP62A and M7 diluted
(1:100) in Trypticase soy broth (TSB; Difco, Detroit, Mich.)
were dispensed into each well of a sterile 96-well polystyrene
microtiter plate (Corning, Corning, N.Y.). The plates were
incubated in humidified conditions at 37°C for 24 h with shak-
ing at 150 rpm. Wells with sterile TSB alone served as controls,
and the mean optical density (OD) values for these wells was
subtracted from the OD values for the test wells. Following
incubation, the liquid was gently aspirated and replaced with
sterile phosphate-buffered saline (PBS; pH 7.3). Each well was
rinsed three times and air dried. Adherent bacteria were fixed
with 95% ethanol and then stained with crystal violet. The OD
at 570 nm (OD570) was measured with a Micro-ELISA Auto-
Reader (DYNEX MRX). Biofilm-producing strains were de-
fined as those with a mean OD570 value 0.1 (21). Biofilm
production by S. epidermidis (RP62A) was confirmed by an OD
of 2.5  0.16. Strain M7 strain did not form a biofilm (OD,
0.08  0.01).
The MIC of vancomycin (Sigma Diagnostics, St. Louis, Mo.)
was determined by broth microdilution in cation-adjusted
Mueller-Hinton broth (CAMHB; Difco) by the procedures
recommended by the National Committee for Clinical Labo-
ratory Standards (NCCLS) (29). The MIC of vancomycin for
S. epidermidis (RP62A) was 2 g/ml. The effect of 5 mM sali-
cylate on the ability of vancomycin to inhibit biofilm formation
was evaluated. Bacterial suspensions were added to serial di-
lutions of vancomycin such that the final inoculum was be-
tween 5  105 and 1  106 CFU/ml. For each trial, performed
in triplicate, viable counts were performed with the inoculum.
The following treatment regimens (final concentrations) in
CAMHB were used: treatment A contained 1 g of vancomy-
cin per ml, treatment B contained 5 mM sodium salicylate and
1 g of vancomycin per ml, treatment C contained 5 mM
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sodium salicylate, and treatment D contained CAMHB alone.
The plates were incubated as described above. The relative
inhibition of biofilm production (expressed as mean percent-
age) was determined as follows: 100  [(OD570 of treated
well/OD570 of reference well)  100]. All treatment regimens
inhibited biofilm production (Table 1). However, sodium sa-
licylate was slightly more effective than 1 g of vancomycin per
ml (one-half the MIC). Vancomycin alone exerted a limited
effect on the adherence and biofilm formation observed here
and in previous studies (3, 28, 33). The combination treatment
(treatment B) was more effective (P  0.022) than treatment
with vancomycin alone. Compared to the reference well, com-
bination treatment reduced biofilm formation by 99.9%, giv-
ing an OD570 value 0.1. Treatments A and C resulted in
some degree of biofilm inhibition, but the bacteria were still
producing a biofilm (Table 1). The OD values produced by the
strain receiving treatment D were lower than those produced
by the same bacterial strain in this assay (Fig. 1). This was most
likely due to the presence of glucose in the TSB used in this
assay but not in CAMHB used in the other assays. Glucose
enhances biofilm production (21). Despite the absence of glu-
cose in CAMHB, remarkable biofilm production was still ob-
served, and treatment regimen D remained appropriate as a
reference for comparison of inhibition of biofilm production.
A polystyrene bead adherence assay was set up with bacte-
rial suspensions between 5  105 and 1  106 CFU/ml. An
aliquot (15 l) of diluted cell suspensions (	107 CFU/ml) was
dispensed into each culture tube containing one sterile poly-
styrene bead (diameter, 5.5 mm; Precision Plastic Ball Co.,
Franklin Park, Ill.) immersed in 300 l of CAMHB, and the
treatment regimens described above were used. The tubes
were incubated in humidified conditions at 37°C for 24 h with
shaking at 150 rpm (model G-10; New Brunswick Scientific
Co., Inc.). Following incubation, the medium was gently aspi-
rated and replaced three times with sterile PBS, and then the
beads were placed into a solution (500 l) containing 0.5%
Tween 80 and 10 mM EDTA for 10 min. The number of
bacteria that adhered to and formed a biofilm on the beads
after treatment was determined by vigorously vortexing (Fi-
scher Vortex-Genie 2, model G-560; Scientific Industries, Inc.,
Bohemia, N.Y.) the beads for 3 min; the liquid was serially
diluted and the bacteria were enumerated by the viable count
method. Ultrasonic treatment was unnecessary for the release
of bacteria, since our preliminary study showed that vortexing
had a recovery efficiency 97%. This is consistent with the
level of biofilm cell removal reported previously (37). When
the effects of the treatments on biofilm formation were deter-
mined, the mean numbers CFU released from the bead in each
control tube served as the reference inoculum for the corre-
sponding experiment. Relative inhibition of biofilm produc-
tion was determined as follows: 100  [(CFU of treated
bead/CFU of reference bead)  100]. In the viable count
assay, the level of inhibition by treatment A was 64.1% and the
level of inhibition by treatment C was 82%. Treatment B was
most effective (significantly more effective than treatment A
[P  0.03]), inhibiting biofilm formation 99.9% (Table 2).
The minimum biofilm eradication concentration (MBEC) of
vancomycin was determined by a broth macrodilution method
in CAMHB, as described by NCCLS, with some modifications.
The MBEC of vancomycin for S. epidermidis biofilms was 8
g/ml and the MIC was 4 g/ml (Table 3). This allowed us to
assess the effect of sodium salicylate on the bactericidal activity
of one-half the MBEC of vancomycin (4 l/ml). Adherent
inocula (between 5  105 and 1.5  106 CFU/bead) were
generated by incubating each bead (with shaking at 37°C) for
18 to 20 h with bacteria (	107 CFU/ml) suspended in
CAMHB. Following incubation, biofilm-coated beads were
rinsed to remove the nonadherent bacteria (37). The number
of bacteria in the biofilm was determined as described above.
Two beads were randomly selected and were used to establish
a representative, mean adherent inoculum for that evaluation.
A standard inoculum size, verified by determination of viable
counts, served as a reference point for assessment of bacterial
killing. Beads colonized with an S. epidermidis biofilm were
placed in selected dilutions of vancomycin, and the mixtures
were incubated at 37°C for 24 h with shaking at 150 rpm. After
incubation, the beads were rinsed as described above. Adher-
ent bacteria were released and enumerated, and the percent
killing of adherent bacteria was calculated as follows: 100 
FIG. 1. Biofilm production by S. epidermidis (RP62A). S. epidermi-
dis M7 was included as a negative control. TSB represents the micro-
titer well that contained only TSB. Strains were tested in quadrupli-
cate. An OD570 0.1 represents biofilm production.
TABLE 1. Summary data (OD values) on inhibition of
S. epidermidis biofilm formationa
No. of triplicate
evaluation
Mean OD570 value (mean % inhibition)
for various treatment regimens
A B C D(reference)
Run 1 0.179 (65.4) 0.000 (99.9) 0.062 (88.0) 0.517
Run 2 0.383 (35.3) 0.001 (99.9) 0.329 (44.4)
Run 3 0.469 (46.8) 0.001 (99.9) 0.225 (74.5)
Total mean (SEM)
% inhibition
49.2 (8.8)b 99.9 (0.04)b 69.1 (12.9)
a An OD570 0.1 represents biofilm production. S. epidermidis suspensions
that gave a final inoculum size that ranged between 5 105 and 1 106 CFU/ml
were introduced to one of the four treatment regimens and were incubated with
shaking (150 rpm) for 24 h at 37°C. Control wells containing CAMHB only, but
no bacteria, were also included. The average ODs derived from these provided
the zero values, which enabled circulation of the relative OD570 values.
b The statistical significance of the relative percentage of biofilm inhibition was
determined, and the difference between treatments A and B was significant (P 
0.022). However, only treatment B prevented biofilm formation. Comparisons of
the means among the groups were done by one-way analysis of variance by
Bonferroni multiple separation tests. Statistical analyses were performed with
Stata software (version 7; Stata Corp., College Station, Tex.).
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[(CFU of treated bead/CFU of untreated bead [reference in-
oculum])  100]. The MBEC was defined as the minimum
concentration of vancomycin required to reduce biofilm cell
numbers (initial inoculum size) 99.9%. Assays were per-
formed in parallel against adherent standard inoculum; treat-
ment A contained 4 g of vancomycin per ml, treatment B
contained 5 mM sodium salicylate and 4 g of vancomycin per
ml, treatment C contained 5 mM sodium salicylate, and treat-
ment D contained CAMHB alone. After incubation, the beads
were processed as described above. Treatment D served as a
reference for evaluation of the efficacy of treatment on biofilm
bacteria. Percent biofilm growth reduction was defined as:
100  [(CFU of treated bead/CFU of reference bead of regi-
men D)  100]. Treatment B exerted a pronounced bacteri-
cidal effect on biofilm bacteria, resulting in a mean reduction in
viable count of3 log10 CFU/bead (99.9%) (Fig. 2). Neither
treatment A nor treatment C had any significant effect on
biofilm eradication. However, they both demonstrated some
bacteriostatic activity against biofilm bacteria (Table 4). In this
work, inhibition of biofilm formation and eradication of estab-
lished biofilms were evaluated with S. epidermidis RP62A
(ATCC 35984), which was isolated from a patient with intra-
vascular catheter-associated sepsis (6). It has been character-
ized as a proficient biofilm producer, thereby making it an ideal
strain for studies on the prevention and treatment of device-
related infections involving bacterial biofilms.
The data presented in Table 4 and Fig. 2 provide compelling
evidence that one-half the MBEC of vancomycin combined
with 5 mM salicylate reduced the viable counts of biofilm cells
99.9%, therefore effectively eradicating established S. epider-
midis biofilms. All treatments had some bacteriostatic effect on
biofilm growth (Table 4).
The mechanisms behind reduced antibiotic susceptibility re-
main a topic of ongoing debate, but unlike the genetically
mediated antibiotic resistance developed by vancomycin-resis-
tant enterococci (VRE) (30), resistance in biofilm-producing
bacteria may be a function of the biofilm itself (7, 14). The
bacteria in biofilms acquire attachment-specific phenotypes,
such as a reduced growth rate, which, in concert with the
extracellular components, make them resistant to conventional
treatment (7, 14). In the biofilm milieu, the extracellular sub-
stance may act as an ion-exchange matrix and may bind to
charged antibiotics, limiting antibiotic availability, diffusion,
and penetration (14).
The concerted effects of salicylate in combination, as pre-
sented here, are not fully understood. Salicylate is a chelator of
divalent cations, and this may have influenced the assay system
in one or more ways, including distortion of the surface charge
on bacterial cell membranes, thereby impairing nutrient up-
take, translocation, adherence, and biofilm formation (9, 12).
As a chelator of divalent cations, salicylate may have depleted
the pool of potential cofactors for enzymes essential for syn-
thesis of the polysaccharide constituents of the biofilm. This
study used 5 mM salicylate, equivalent to 	800 g/ml, a con-
centration above the therapeutic range for aspirin (200 to 350
g/ml). However, 5 mM has been among the lower concentra-
tions of this drug used in studies of bacteriology (17, 28),
TABLE 2. Summary data (polystyrene beads) on inhibition of S. epidermidis biofilm formationa
No. of duplicate
evaluation
Mean no. of CFU/bead from
various treatment regimens
A B C D (reference)
Run 1 1.9  105 (78.4) 7.4  102 (99.9) 1.7  105 (80.7) 8.8  105
Run 2 5.5  104 (72.9) 4.8  102 (99.8) 4.1  104 (79.8) 2.1  105
Run 3 1.3  105 (40.9) 2.1  102 (99.9) 3.2  104 (85.5) 2.2  105
Total mean (SEM) % inhibition 64.1 (11.7)b 99.9 (0.04)b 82.0 (1.8)
a The viable counts were compared with those recovered from beads incubated in the reference treatment (treatment D). S. epidermidis suspensions that gave a final
inoculum size that ranged between 5  105 and 1  106 CFU/ml were introduced to one of the four treatment regimens and incubated with shaking (150 rpm) for 24 h
at 37°C.
b The statistical significance of the relative percentage of biofilm inhibtion was determined, and the difference between treatments A and B was significant (P 0.03).
However, only treatment B effectively inhibited biofilm formation. Comparisons of the mean among the groups were tested by one-way analysis of variance by
Bonferroni multiple separation tests. Statistical analyses were performed with Stata software (version 7; Stata Corp.).
TABLE 3. MBECs of vancomycin for S. epidermidis biofilmsa
No. of duplicate
evaluation
Inoculum
sizeb
No. of viable cells recovered (no. of CFU/bead) for vancomycin concn (g/ml) of:
10 8 6 4 2 0
Run 1 7 105 1 101 (, 99.9)c 9 101 (, 99.9) 4 102 (, 99.9) 3 106 (, 0) NA () NA ()
Run 2 5.3  105 1.9 101 (, 99.9) 2.5 101 (, 99.9) 7.5 103 (, 98.59) 1.9 106 (, 0) NA () NA ()
Run 3 1.2  106 1 101 (, 99.99) 3.1 102 (, 99.97) 9.1 102 (, 99.92) 6.5 105 (, 45.8) NA () NA ()
Mean percent biofilm
eradication
99.9 99.9 99.48 15.3
a S. epidermidis biofilms growing on beads (5.3  105 to 1.2  106 CFU/bead) were subjected to three independent test evaluations.
b For each evaluation, a representative inoculum size was established by determining the mean number of CFU per bead for at least two untreated, biofilm-colonized
beads that were randomly selected. This value served as a reference for comparison with viable biofilm cell counts for beads exposed to the various vancomycin
concentrations. NA, not applicable (therefore, no further assessment was done).
c Information in parentheses represents the growth turbidity (, turbid [visible growth in tube]; , no visible growth, i.e., inhibition of growth), percent eradication.
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suggesting its appropriateness in our research efforts to better
understand salicylate’s potential role in combined therapy.
Prophylactic administration of vancomycin or teicoplanin
during catheter insertion fails to prevent intravascular cathe-
ter-related bloodstream infections (19, 25; G. Pellizzer, R.
Nicolin, A. D’Emilio, G. Figoli, L. Bragagnolo, and F. Merio,
Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. J89, p. 273, 1995). To reduce the risk of acquisition of
VRE, the Centers for Disease Control and Prevention has
recommended against the use of these antibiotics as prophy-
laxis (4). Our in vitro studies, however, indicate that the anti-
staphylococcal efficacy of vancomycin is significantly enhanced
when vancomycin is used in conjunction with salicylate. Fur-
ther work is needed to determine if this combination is clini-
cally useful for the prevention or treatment of intravascular
device-related infections.
In conclusion, this study has shown that (i) sodium salicylate
significantly enhances the antistaphylococcal activity of vanco-
mycin, (ii) a combination of one-half the MIC of vancomycin
and 5 mM salicylate effectively prevents biofilm formation, and
(iii) a combination of one-half the MBEC of vancomycin and
5 mM sodium salicylate effectively kills the bacteria in biofilms,
reducing the viable biofilm cell numbers by 3 log10 CFU. If the
in vitro data presented herein could be confirmed in vivo with an
appropriate animal model, the salicylate-vancomycin combina-
tion may be useful for the prevention and treatment of intra-
vascular catheter-related infections caused by S. epidermidis.
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